{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:01:19Z","timestamp":1778670079698,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001207","name":"Department of Health, New South Wales Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12889-017-5018-9","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T12:14:18Z","timestamp":1517573658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial"],"prefix":"10.1186","volume":"18","author":[{"name":"on behalf of the EPIC-NSW study group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-2197","authenticated-orcid":false,"given":"Iryna B.","family":"Zablotska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Selvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Guy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Holden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather-Marie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"McNulty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janaki","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew E.","family":"Grulich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"key":"5018_CR1","doi-asserted-by":"crossref","unstructured":"Cohen MS, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med. 2011;365(6):493\u2013505.","DOI":"10.1056\/NEJMoa1105243"},{"key":"5018_CR2","unstructured":"NSW Government,MInistry of Health. NSW HIV strategy 2012\u20132015: A new era. Sydney, NSW, 2012. Available online at http:\/\/www.health.nsw.gov.au\/endinghiv\/Publications\/HIV-strategy.pdf . Accessed 30 December 2017."},{"issue":"9","key":"5018_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"JD Lundgren","year":"2015","unstructured":"INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, F\u00e4tkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795\u2013807.","journal-title":"N Engl J Med"},{"key":"5018_CR4","unstructured":"The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2014. The Kirby Institute, UNSW, Sydney NSW 2052. Last accesssed on 2 March 2015."},{"key":"5018_CR5","unstructured":"NSW Government. Ministry of Health. NSW HIV Strategy 2016\u20132020 Quarter 4 & Annual 2016 Data Report. Availalbe online at http:\/\/www.health.nsw.gov.au\/endinghiv\/Documents\/q4-2016-annual-hiv-data-report.pdf . Accessed 19 Apr 2017."},{"key":"5018_CR6","unstructured":"Gray R. NSW HIV Cascade - 2015. Unpublished analyses. Kirby Institute, UNSW. February 2017."},{"key":"5018_CR7","unstructured":"NSW Government. Ministry of Health. NSW HIV Strategy 2012-2015 Annual Quarter 4 2015 Data Report. Availalbe online at http:\/\/www.health.nsw.gov.au\/endinghiv\/Documents\/q4-2015-and-annual-hiv-data-report.pdf . Accessed 7 June 2017."},{"issue":"1","key":"5018_CR8","doi-asserted-by":"publisher","first-page":"20526","DOI":"10.7448\/IAS.18.1.20526","volume":"18","author":"M Holt","year":"2015","unstructured":"Holt M, et al. The prevalence and correlates of undiagnosed HIV among Australian gay and bisexual men: results of a national, community-based, bio-behavioural survey. J Int AIDS Soc. 2015;18(1):20526.","journal-title":"J Int AIDS Soc"},{"key":"5018_CR9","doi-asserted-by":"publisher","unstructured":"Hull, P., Mao, L., Kolstee, J., Duck, T., Feeney, L., Prestage, G., Zablotska, I., Lea, T., de Wit, J., & Holt, M. (2016). Gay Community Periodic Survey: Sydney 2016. Sydney: Centre for Social Research in Health, UNSW Australia. Available online at https:\/\/doi.org\/10.4225\/53\/57A049A3D5763 . Accessed 12 Dec 2016.","DOI":"10.4225\/53\/57A049A3D5763"},{"key":"5018_CR10","unstructured":"NSW HIV Strategy 2016-2020 - NSW health. Available online at: http:\/\/www.health.nsw.gov.au\/endinghiv\/Publications\/nsw-hiv-strategy-2016-2020.pdf . Accessed 10 Jan 2016."},{"issue":"27","key":"5018_CR11","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. NEnglJMed. 2010;363(27):2587\u201399.","journal-title":"NEnglJMed"},{"issue":"23","key":"5018_CR12","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","volume":"373","author":"JM Molina","year":"2015","unstructured":"Molina JM, et al. On-demand Preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237\u201346.","journal-title":"N Engl J Med"},{"issue":"10013","key":"5018_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","volume":"387","author":"S McCormack","year":"2016","unstructured":"McCormack S, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53\u201360.","journal-title":"Lancet"},{"issue":"12","key":"5018_CR14","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","volume":"30","author":"VA Fonner","year":"2016","unstructured":"Fonner VA, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973\u201383.","journal-title":"AIDS"},{"issue":"3","key":"5018_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa051871","volume":"354","author":"JE Gallant","year":"2006","unstructured":"Gallant JE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N.Engl.J.Med. 2006;354(3):251\u201360.","journal-title":"N.Engl.J.Med"},{"issue":"4","key":"5018_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/01.qai.0000167155.44980.e8","volume":"39","author":"T Hawkins","year":"2005","unstructured":"Hawkins T, et al. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J.Acquir.Immune.Defic.Syndr. 2005;39(4):406\u201311.","journal-title":"J.Acquir.Immune.Defic.Syndr."},{"issue":"3","key":"5018_CR17","first-page":"329","volume":"47","author":"M Vourvahis","year":"2008","unstructured":"Vourvahis M, et al. The pharmacokinetics and viral activity of tenofovir in the male genital tract. JAcquirImmuneDeficSyndr. 2008;47(3):329\u201333.","journal-title":"JAcquirImmuneDeficSyndr"},{"issue":"12","key":"5018_CR18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1089\/apc.2014.0195","volume":"28","author":"AY Liu","year":"2014","unstructured":"Liu AY, et al. Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation. AIDS Patient Care STDs. 2014;28(12):622\u20137.","journal-title":"AIDS Patient Care STDs"},{"key":"5018_CR19","unstructured":"US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States \u2013 2014. A clinical practice guideline. Available online:: http:\/\/www.cdc.gov\/hiv\/pdf\/guidelines\/PrEPguidelines2014.pdf . Accessed 30 Dec 2017."},{"key":"5018_CR20","unstructured":"European AIDS clinical society. Guidelines Version 8.0 October 2015. Available online at: http:\/\/www.eacsociety.org\/files\/2015_eacsguidelines_8_0-english_rev-20160124.pdf . Accessed 10 Jan 2016."},{"key":"5018_CR21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S2055-6640(20)30338-1","volume":"3","author":"E Wright","year":"2017","unstructured":"Wright E, Grulich A, Roy K, Boyd M, Cornelisse V, Russell D, O\u2019Donnell D, Witthaker B, Crooks L, Zablotska I. Australasian society for HIV, viral hepatitis and sexual health medicine HIV pre-exposure prophylaxis: clinical guidelines. Journal of Virus Eradication. 2017;3:168\u201384.","journal-title":"Journal of Virus Eradication"},{"key":"5018_CR22","unstructured":"World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September 2015. NLM classification: WHO\/WC 503.2. Available online at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/186275\/1\/9789241509565_eng.pdf . Accessed 29 July 2016."},{"key":"5018_CR23","unstructured":"Australian Government Department of Health, Therapeutic Goods Administration. Prescription medicines: new or extended uses, or new combinations of registered medicines: Extension of Indications' registrations, May 2016: Truvada. Available online at: https:\/\/www.tga.gov.au\/prescription-medicines-new-or-extended-uses-registered-medicines . Accessed 1 July 2016."},{"key":"5018_CR24","unstructured":"NSW Government, Ministry of Health. Pre-Exposure Prophylaxis of HIV with Antiretroviral Medications: Guideline. Prepared by Dr. Iryna Zablotska on behalf of the NSW PrEP guidelines and clinical delivery group. Availalbe online at: http:\/\/www1.health.nsw.gov.au\/pds\/ActivePDSDocuments\/GL2016_011.pdf . Accessed 18 May 2017."},{"key":"5018_CR25","doi-asserted-by":"crossref","unstructured":"Vaccher S, et al. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW demonstration project PRELUDE. BMJ Open.\u00a02016;20;6(6):e012179.","DOI":"10.1136\/bmjopen-2016-012179"},{"issue":"3","key":"5018_CR26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/QAI.0b013e31827e854a","volume":"62","author":"IB Zablotska","year":"2013","unstructured":"Zablotska IB, et al. The informal use of antiretrovirals for preexposure prophylaxis of HIV infection among gay men in Australia. J Acquir Immune Defic Syndr. 2013;62(3):334\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"5018_CR27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1136\/sextrans-2011-050312","volume":"88","author":"M Holt","year":"2012","unstructured":"Holt M, et al. Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex TransmInfect. 2012;88(4):258\u201363.","journal-title":"Sex TransmInfect"},{"key":"5018_CR28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.33321\/cdi.2010.34.32","volume":"34","author":"RJ Guy","year":"2010","unstructured":"Guy RJ, Kong F, Goller J, Franklin N, Bergeri I, Dimech W, et al. A new national chlamydia surveillance system in Australia: evaluation of the first stage implementation. Commun Dis Intell Q Rep. 2010;34:319\u201328.","journal-title":"Commun Dis Intell Q Rep"},{"key":"5018_CR29","unstructured":"Australian Bureau of Statistics (ABS). Population by Age and Sex, Regions of Australia, June 2014. Available online at http:\/\/www.abs.gov.au\/AUSSTATS\/abs@.nsf\/DetailsPage\/3235.02014?OpenDocument . Accessed 18 Oct 2016. Canberra."},{"issue":"5","key":"5018_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1071\/SH14122","volume":"11","author":"AE Grulich","year":"2014","unstructured":"Grulich AE, et al. Homosexual experience and recent homosexual encounters: the second Australian study of health and relationships. Sex Health. 2014;11(5):439\u201350.","journal-title":"Sex Health"},{"key":"5018_CR31","unstructured":"HIV Diagnosis and Care Cascade in 'HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2017\u2032. The Kirby Institute, UNSW Australia, Sydney NSW 2052.(pending release)."},{"issue":"3","key":"5018_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1071\/SH10125","volume":"8","author":"IB Zablotska","year":"2011","unstructured":"Zablotska IB, et al. Behavioural surveillance among gay men in Australia: methods, findings and policy implications for the prevention of HIV and other sexually transmissible infections. Sex Health. 2011;8(3):272\u20139.","journal-title":"Sex Health"},{"key":"5018_CR33","unstructured":"Australian Federation of AIDS Organisations (AFAO). We can end HIV by 2020. Available online at: http:\/\/endinghiv.org.au .\u00a0Accessed 10 Feb 2016."},{"key":"5018_CR34","unstructured":"Australian STI management guidelines for use in primary care. Availalbe online at: http:\/\/www.sti.guidelines.org.au . Accessed 18 May 2017."},{"key":"5018_CR35","unstructured":"ASHM. National guidelines for post-exposure prophylaxis after non-occupational exposure to HIV. Australian Government Department of Health and Aging, 2013."},{"key":"5018_CR36","unstructured":"NSW Government. NSW Health Telehealth Framework and Implementation Strategy 2016\u20132021. Available online at: http:\/\/www.health.nsw.gov.au\/telehealth\/Publications\/NSW-telehealth-framework.pdf . Accessed 18 May 2017."},{"key":"5018_CR37","unstructured":"ASHM. Antiretroviral guidelines. Welcome to the Australian Commentary on the US Department of Health and Human Services (DHHS) Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available online at: http:\/\/arv.ashm.org.au . Accessed 30 Dec 2017."},{"issue":"1","key":"5018_CR38","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1186\/s12879-016-2073-2","volume":"16","author":"D Callander","year":"2016","unstructured":"Callander D, et al. A longitudinal cohort study of HIV 'treatment as prevention' in gay, bisexual and other men who have sex with men: the treatment with Antiretrovirals and their impact on positive and negative men (TAIPAN) study protocol. BMC Infect Dis. 2016;16(1):752.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"5018_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/QAD.0b013e32831fb51a","volume":"23","author":"F Jin","year":"2009","unstructured":"Jin F, et al. Unprotected anal intercourse, risk reduction behaviours, and subsequent HIV infection in a cohort of homosexual men. AIDS. 2009;23(2):243\u201352.","journal-title":"AIDS"}],"updated-by":[{"DOI":"10.1186\/s12889-018-5173-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000}}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-017-5018-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T13:20:30Z","timestamp":1751289630000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-017-5018-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5018"],"URL":"https:\/\/doi.org\/10.1186\/s12889-017-5018-9","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]},"assertion":[{"value":"30 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"After publication of the article [1], it has been brought to our attention that one of the members of the EPIC-NSW study group has had their name spelt incorrectly in the acknowledgements. The article mentions \u201cMuhammad Hammoud\u201d when in fact the correct spelling is \u201cMohamed Hammoud\u201d.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol is approved by the St. Vincent\u2019s Hospital, Sydney, Australia HREC (primary review, protocol number 1511; reference number HREC\/15\/SVH\/436) and ACON HREC (reference number RERC2015\/23). Theidentifying number is NCT02870790. Site-specific assessments are obtained from each public health service\u2019s Research Office. The design and implementation of this study follows The Declaration of Helsinki and European Committee for Proprietary Medicinal Products\/ International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (CPMP\/ICH) Guidelines for Good Clinical Practice. All EPIC-NSW participants have provided written informed consent to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DAC has received honoraria from Gilead Sciences, ViiV and Merck Sharp & Dohme. AG has received research funding from BioCSL Ltd., Viiv and Gilead Sciences, as well as conference travel funding and honoraria for educational presentations from Merck. IZ has received funding and supply of the study medication from Gilead Sciences. DS has received funding to attend local (within Australia) educational events from Gilead, and funding from ViiV, BMS, Merck, Roche, Boehringer Ingleheim and Gilead to hold local education events for health practitioners. CS, H-MS, JA, FJ, JH, KP, RG have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"210"}}